These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20530022)

  • 41. Diabetes with coronary disease--a moving target amid evolving therapies?
    Boden WE; Taggart DP
    N Engl J Med; 2009 Jun; 360(24):2570-2. PubMed ID: 19502646
    [No Abstract]   [Full Text] [Related]  

  • 42. Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results.
    Chaitman BR; Hadid M; Laddu AA
    Curr Opin Cardiol; 2010 Nov; 25(6):597-602. PubMed ID: 20885315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapies for type 2 diabetes and coronary artery disease.
    Pfisterer ME; Zellweger MJ
    N Engl J Med; 2009 Oct; 361(14):1407; author reply 1409-10. PubMed ID: 19797290
    [No Abstract]   [Full Text] [Related]  

  • 44. BARI 2D: headlines are not enough.
    King SB
    JACC Cardiovasc Interv; 2009 Aug; 2(8):809-10. PubMed ID: 19695556
    [No Abstract]   [Full Text] [Related]  

  • 45. [Critical notes on the results of studies (ACCORD, ADVANCE, VADT) of the efficiency of intensive therapy of type 2 diabetes mellitus].
    Schwartz V
    Klin Med (Mosk); 2011; 89(3):18-20. PubMed ID: 21861397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Grogan M; Jenkins M; Sansing VV; MacGregor J; Brooks MM; Julien-Williams P; Amendola A; Abbott JD;
    Diabetes Educ; 2010; 36(5):774-83. PubMed ID: 20584997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical studies on coronary revascularization in patients with type 2 diabetes.
    Mak KH; Faxon DP
    Eur Heart J; 2003 Jun; 24(12):1087-103. PubMed ID: 12804923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gap between clinical trials and clinical practice: lessons from the Bypass Angioplasty Revascularization Investigation (BARI).
    Frye RL; Brooks MM; Nesto RW;
    Circulation; 2003 Apr; 107(14):1837-9. PubMed ID: 12695282
    [No Abstract]   [Full Text] [Related]  

  • 49. Why Optimal Medical Therapy Should Be a Universal Standard of Care.
    Maron DJ; Boden WE
    J Am Coll Cardiol; 2015 Aug; 66(7):774-776. PubMed ID: 26271058
    [No Abstract]   [Full Text] [Related]  

  • 50. Type-2 diabetes mellitus and cardiovascular disease.
    Henning RJ
    Future Cardiol; 2018 Nov; 14(6):491-509. PubMed ID: 30409037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Letter by Liu et al regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
    Liu W; Chen M; Huang DJ
    Circulation; 2014 Apr; 129(16):e459. PubMed ID: 24753556
    [No Abstract]   [Full Text] [Related]  

  • 52. What cardiologists need to know about diabetes.
    Webster MW; Scott RS
    Lancet; 1997 Jul; 350 Suppl 1():SI23-8. PubMed ID: 9250280
    [No Abstract]   [Full Text] [Related]  

  • 53. Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial.
    Jamil Y; Park DY; Verde LM; Sherwood MW; Tehrani BN; Batchelor WB; Frampton J; Damluji AA; Nanna MG
    Am J Cardiol; 2024 Mar; 214():66-76. PubMed ID: 38160927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of coronary artery disease in patients with type 2 diabetes mellitus.
    Srikanth S; Deedwania P
    Curr Cardiol Rep; 2007 Jul; 9(4):264-71. PubMed ID: 17601392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ACCORD(ing) to a trialist.
    Pfeffer MA
    Circulation; 2010 Aug; 122(8):841-3. PubMed ID: 20733111
    [No Abstract]   [Full Text] [Related]  

  • 56. Medical economics and the assessment of value in cardiovascular medicine: Part II.
    Mark DB; Hlatky MA
    Circulation; 2002 Jul; 106(5):626-30. PubMed ID: 12147547
    [No Abstract]   [Full Text] [Related]  

  • 57. [Not Available].
    Soeiro Ade M; Mansur Ade P; Schaan BD; Caramelli B; Rochitte CE; Serrano CV; Garzillo CL; Calderaro D; Gualandro DM; Lima EG; Marcondes-Braga FG; Lima FG; Oliveira FM; Azevedo FR; Chauhan H; Salles JE; Soares J; Cardoso JN; Pellanda LC; Sacilotto L; Baracioli L; Bortolotto LA; César LA; Ochiai ME; Minami MH; Pinheiro MB; Moretti MA; Oliveira MT; Rezende PC; Lemos PA; Admoni SN; Lottenberg SA; Rocha VZ; Hueb W; Mathias W
    Arq Bras Cardiol; 2014 May; 102(5 Suppl 1):1-41. PubMed ID: 27223869
    [No Abstract]   [Full Text] [Related]  

  • 58. Modifications of coronary risk factors.
    Albu J; Gottlieb SH; August P; Nesto RW; Orchard TJ;
    Am J Cardiol; 2006 Jun; 97(12A):41G-52G. PubMed ID: 16813737
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D).
    Chung SC; Hlatky MA; Stone RA; Rana JS; Escobedo J; Rogers WJ; Bromberger JT; Kelsey SF; Brooks MM
    Am Heart J; 2011 Jul; 162(1):184-92.e3. PubMed ID: 21742107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiac dysfunction in diabetes.
    Gardner JD; Murray DB; Wold LE
    Life Sci; 2013 Mar; 92(11):599-600. PubMed ID: 23142651
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.